Merck & Co., Inc. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Merck & Co., Inc. treasury stock, value, acquired, cost method for the quarter ending 2026-06-30 was $712.00M, a 47.06% decline year-over-year.
- Merck & Co., Inc. treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $925.00M, a 20.53% decline year-over-year.
- Merck & Co., Inc. treasury stock, value, acquired, cost method for the quarter ending 2025-12-31 was $1.25B, a 156.03% increase year-over-year.
- Merck & Co., Inc. treasury stock, value, acquired, cost method for the quarter ending 2025-09-30 was $1.32B, a 198.20% increase year-over-year.
- Merck & Co., Inc. treasury stock, value, acquired, cost method for fiscal 2025 was $5.08B, a 289.28% increase from fiscal 2024.
- Merck & Co., Inc. treasury stock, value, acquired, cost method for fiscal 2024 was $1.31B, a 2.97% decline from fiscal 2023.
- Merck & Co., Inc. treasury stock, value, acquired, cost method for fiscal 2023 was $1.35B.
- Merck & Co., Inc. treasury stock, value, acquired, cost method for fiscal 2021 was $840.00M, a 34.43% decline from fiscal 2020.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-06-30 | $712.00M 10-Q · filed 2026-08-07 | $4.21B derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $925.00M 10-Q · filed 2026-05-04 | $4.85B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.25B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.08B 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.32B 10-Q · filed 2025-11-05 | $4.32B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.34B 10-Q · filed 2026-08-07 | $3.44B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.16B 10-Q · filed 2026-05-04 | $2.35B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $489.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.31B 10-K · filed 2026-02-24 |
| 2024-09-30 | $444.00M 10-Q · filed 2025-11-05 | $1.21B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $251.00M 10-Q · filed 2025-08-05 | $1.23B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $122.00M 10-Q · filed 2025-05-02 | $1.32B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $393.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.35B 10-K · filed 2026-02-24 |
| 2023-09-30 | $466.00M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $338.00M 10-Q · filed 2024-08-05 | |
| 2023-03-31 | $149.00M 10-Q · filed 2024-05-03 | |
| 2021-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $840.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $583.00M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $239.00M 10-Q · filed 2022-08-05 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $1.28B 10-K · filed 2023-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $2.33B derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.74B derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $1.28B 10-Q · filed 2021-05-05 | $4.97B derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $1.05B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $4.78B 10-K · filed 2022-02-25 |
| 2019-09-30 | $1.41B 10-Q · filed 2020-11-05 | $9.66B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.24B 10-Q · filed 2020-08-05 | $9.25B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.09B 10-Q · filed 2020-05-06 | $9.62B derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $5.93B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $9.09B 10-K · filed 2021-02-25 |
| 2018-09-30 | $996.00M 10-Q · filed 2019-11-05 | $4.86B derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $1.60B 10-Q · filed 2019-08-06 | $4.02B derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $566.00M 10-Q · filed 2019-05-08 | $3.56B derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $1.70B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $4.01B 10-K · filed 2020-02-26 |
| 2017-09-30 | $159.00M 10-Q · filed 2018-11-06 | $3.33B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $1.13B derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $4.01B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $1.02B 10-Q · filed 2018-05-08 | $3.54B derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $1.02B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.43B 10-K · filed 2019-02-27 |
| 2016-09-30 | $845.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.60B derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $660.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $4.04B derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $913.00M 10-Q · filed 2017-05-09 | $4.08B derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $1.18B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $4.19B 10-K · filed 2018-02-27 |
| 2015-09-30 | $1.28B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $4.63B derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $709.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $6.01B derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $1.01B 10-Q · filed 2016-05-09 | $7.55B derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $1.62B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $7.70B 10-K · filed 2017-02-28 |
| 2014-09-30 | $2.67B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $6.28B derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $2.25B derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $3.82B derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $1.17B 10-Q · filed 2015-05-07 | $7.10B derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $196.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $6.52B 10-K · filed 2016-02-26 |
| 2013-09-30 | $215.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $7.47B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $5.53B derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $7.71B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $580.00M 10-Q · filed 2014-05-08 | $2.71B derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $1.15B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $2.59B 10-K · filed 2015-02-27 |
| 2012-09-30 | $454.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $2.00B derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $529.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $2.59B derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $456.00M 10-Q · filed 2013-05-09 | |
| 2011-12-31 | $562.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $1.92B 10-K · filed 2014-02-27 |
| 2011-09-30 | $1.04B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $1.59B 10-K · filed 2013-02-28 |
| 2010-09-30 | $296.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | |
| 2008-12-31 | $2.73B 10-K · filed 2011-02-28 | |
| 2007-12-31 | -$1.43B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |